Skip to main content
Log in

Assessment of the Efficacy of Preventive Therapy with Chaperone Inducer U133 in a Model of the Preclinical Stage of Parkinson’s Disease in Elderly Rats

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Parkinson’s disease (PD) is a chronic relentlessly progressive neurodegenerative disease mainly affecting dopamine (DA)-ergic neurons in the nigrostriatal system of the brain. PD mostly affects elderly people and is incurable. Impairments to the conformation of α-synuclein protein and its hyperphosphorylation, along with the development of chronic neuroinflammation, are the main components in the pathogenesis of neurodegeneration in PD. Pharmacotherapy directed to mobilizing the stress-induced chaperone Hsp70, which plays a key role in controlling the quality of protein molecules and has immunomodulatory activity, has potential in developing preventive treatment for PD. This study used a model of the preclinical stage of PD in elderly rats created by intranasal administration of proteasome inhibitor lactacystin. Rats were treated with a scheme based on systemic administration of an Hsp70 chaperone inducer – the low molecular weight quinoid compound U133 (acetylated echinochrome 2,3,7-tris-O-glucoside). Compound U133 was found to induce a time-delayed increase in Hsp70 content in the pars compacta of the substantia nigra (SNpc) in elderly animals. Preventive Hsp70-induced therapy with U133 in the model of the preclinical stage of PD in elderly rats weakened the process of neurodegeneration in the SNpc and countered the development of neuroinflammation. There were reductions in the quantity of aggregated α-synuclein and regression of α-synuclein posttranslationally modified by phosphorylation at Ser129. These data provide evidence that the prodrug, low molecular weight substance U133, has significant therapeutic potential in the development of Parkinson’s-like pathology at elderly age. The study results have scientific and applied importance in terms of the development of innovatory technologies for the preventive pharmacotherapy of PD based on the Russian substance U133.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M. G. Erkkinen, M. O. Kim, and M. D. Geschwind, “Clinical neurology and epidemiology of the major neurodegenerative diseases,” Cold Spring Harb. Perspect. Biol., 10, No. 4, a033118 (2018).

  2. K. A. Fujita, M. Ostaszewski, Y. Matsuoka, et al., “Integrating pathways of Parkinson’s disease in a molecular interaction map,” Mol. Neurobiol., 49, No. 1, 88–102 (2014).

    Article  CAS  Google Scholar 

  3. H. Braak, E. Ghebremedhin, U. Rüb, et al., “Stages in the development of Parkinson’s disease-related pathology,” Cell Tissue Res., 318, No. 1, 121–134 (2004).

    Article  Google Scholar 

  4. M. Verma, S. Basu, M. Singh, et al., “Molecular interactions of a-synuclein, mitochondria, and cellular degradation pathways in Parkinson’s disease,” Qual. Control Cell. Protein Neurodegener. Disord., 212–234 (2020).

  5. E. M. Rocha, B. De Miranda, and L. H. Sanders, “Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease,” Neurobiol. Dis., 109, 249–257 (2018).

    Article  CAS  Google Scholar 

  6. B. I. Giasson, J. E. Duda, I. V. J. Murray, et al., “Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions,” Science, 290, No. 5493, 985–989 (2000).

  7. J. Lotharius and P. Brundin, “Pathogenesis of Parkinson’s disease: Dopamine, vesicles and α-synuclein,” Nat. Rev. Neurosci., 3, No. 12, 932–942 (2002).

    Article  CAS  Google Scholar 

  8. S. Hara, S. Arawaka, H. Sato, et al., “Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner,” Mol. Biol. Cell., 24, No. 11, 1649–1660 (2013).

    Article  CAS  Google Scholar 

  9. O. Marques and T. F. Outeiro, “Alpha-synuclein: From secretion to dysfunction and death,” Cell Death Dis., 3, No. 7, e350 (2012).

  10. J. C. Rochet, T. F. Outeiro, K. A. Conway, et al., “Interactions among α-synuclein, dopamine, and biomembranes: Some clues for understanding neurodegeneration in Parkinson’s disease,” J. Mol. Neurosci., 23, No. 1–2, 23–33 (2004).

    Article  CAS  Google Scholar 

  11. M. Subramaniam, D. Althof, S. Gispert, et al., “Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels,” J. Neurosci., 34, No. 41, 13586–13599 (2014).

    Article  Google Scholar 

  12. C. C. Ferrari, M. C. Pott Godoy, R. Tarelli, et al., “Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra,” Neurobiol. Dis., 24, No. 1, 183–193 (2006).

    Article  CAS  Google Scholar 

  13. S. Perez-Alvarez, M. E. Solesio, J. Manzanares, et al., “Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death,” Br. J. Pharmacol., 158, No. 4, 1121–1130 (2009).

    Article  CAS  Google Scholar 

  14. M. N. Karpenko, Z. M. Muruzheva, N. S. Pestereva, and I. V. Ekimova, “An infection hypothesis of Parkinson’s disease,” Neurosci. Behav. Physiol., 49, No. 5, 555–561 (2019).

    Article  Google Scholar 

  15. P. K. Auluck, H. Y. E. Chan, J. Q. Trojanowski, et al., “Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease,” Science, 295, No. 5556, 865–868 (2002).

  16. J. B. Leverenz, I. Umar, Q. Wang, et al., “Proteomic identification of novel proteins in cortical Lewy bodies,” Brain Pathol., 17, No. 2, 139–145 (2007).

    Article  CAS  Google Scholar 

  17. Y. Chu, H. Dodiya, P. Aebischer, et al., “Alterations in lysosomal and proteasomal markers in Parkinson’s disease: Relationship to alphasynuclein inclusions,” Neurobiol. Dis., 35, No. 3, 385–398 (2009).

    Article  CAS  Google Scholar 

  18. Y. F. Pastukhov, D. V. Plaksina, K. V. Lapshina, et al., “Exogenous protein HSP70 blocks neurodegeneration in the rat model of the clinical stage of Parkinson’s disease,” Dokl. Biol. Sci., 457, No. 1 (2014).

  19. D. V. Belan and I. V. Ekimova, “Heat shock proteins in conformational diseases of the brain,” Ros. Fiziol. Zh., 105, No. 12, 1465–1485 (2019).

    Article  CAS  Google Scholar 

  20. E. M. Eremenko, O. I. Antimonova, O. G. Shekalova, et al., “Novel compounds that increase expression of Hsp70 and their biological activity,” Cell Tiss. Biol., 4, No. 3, 251–257 (2010).

    Article  Google Scholar 

  21. V. F. Lazarev, K. V. Onokhin, O. I. Antimonova, et al., “Kinetics of chaperone activity of proteins Hsp70 and Hdj1 in human leukemia u-937 cells after preconditioning with thermal shock or compound u-133,” Biochemistry, 76, No. 5, 590 (2011).

  22. I. V. Ekimova, D. V. Plaksina, Y. F. Pastukhov, et al., “New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson’s disease,” Exp. Neurol., 306, 199–208 (2018).

    Article  CAS  Google Scholar 

  23. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson’s disease,” Lancet Neurol., 5, No. 6, 525–535 (2006).

    Article  Google Scholar 

  24. J. Labbadia and R. I. Morimoto, “The biology of proteostasis in aging and disease,” Annu. Rev. Biochem., 84, No. 1, 435–464 (2015).

    Article  CAS  Google Scholar 

  25. C. Soti and P. Csermely, “Chaperones and aging: Role in neurodegeneration and in other civilizational diseases,” Neurochem. Int., 41, No. 6, 383–389 (2002).

    Article  CAS  Google Scholar 

  26. D. A. Jurivich, M. Choo, J. Welk, et al., “Human aging alters the first phase of the molecular response to stress in T-cells,” Exp. Gerontol., 40, No. 12, 948–958 (2005).

    Article  CAS  Google Scholar 

  27. I. V. Ekimova, V. V. Simonova, M. A. Guzeev, et al., “Changes in sleep characteristics of rat preclinical model of Parkinson’s disease based on attenuation of the ubiquitin-proteasome system activity in the brain,” J. Evol. Biochem. Physiol., 52, No. 6, 463–474 (2016).

    Article  CAS  Google Scholar 

  28. S. Polonik, A. Tolkach, and N. S. Uvarova, “Glycosylation of echinochrome and related hydroxynaphthazarines by the orthoester method,” Zh. Organ. Khim., 30, No. 2, 248–253 (1994).

    CAS  Google Scholar 

  29. N. P. Mishchenko, S. A. Fedoreyev, and V. L. Bagirova, “Histochrome: a new original domestic drug,” Pharm. Chem. J., 37, No. 1, 48-52 (2003).

    Article  CAS  Google Scholar 

  30. V. F. Lazarev, A. D. Nikotina, E. R. Mikhaylova, et al., “Hsp70 chaperone rescues C6 rat glioblastoma cells from oxidative stress by sequestration of aggregating GAPDH,” Biochem. Biophys. Res. Commun, 470, No. 3, 766–771 (2016).

    Article  CAS  Google Scholar 

  31. E. A. Yurchenko, E. S. Menchinskaya, S. G. Polonik, et al., “Hsp70 induction and anticancer activity of U-133, the acetylated trisglucosydic derivative of echinochrome,” Med. Chem., 5, No. 6, 263–271 (2015).

    Article  Google Scholar 

  32. E. B. Lasunskaia, I. Fridlianskaia, A. V. Arnoldt, et al., “Sublethal heat shock induces plasma membrane translocation of 70-kDa heat shock protein in viable, but not in apoptotic, U-937 leukaemia cells,” APMIS, 118, No. 3, 179–187 (2010).

  33. D. V. Plaksina, M. V. Chernyshev, M. N. Karpenko, et al., “Experimental modeling of a preclinical Parkinson’s disease stage in rats by intranasal lactacystin administration,” Neurodegen. Dis., Supplement, 17, No. 1, 1655 (2017).

  34. I. V. Ekimova, A. R. Gazizova, M. N. Karpenko, and D. V. Plaksina, “Signs of anhedonia and destructive changes in the ventral tegmental area of the midbrain in the model of the preclinical Parkinson’s disease stage in experiment,” Zh. Nevrol. Psikhiat., 118, No. 9, 61–67 (2018).

    Article  CAS  Google Scholar 

  35. I. N. Abdurasulova, I. V. Ekimova, A. V. Matsulevich, et al., “Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson’s disease,” Dokl. Biol. Sci., 476, No. 1, 188–190 (2017).

    Article  CAS  Google Scholar 

  36. Y. F. Pastukhov, V. V. Simonova, M. V. Chernyshev, et al., “Signs of sleep and behavior disorders indicating the initial stage of neurodegeneration in a rat model of Parkinson’s disease,” J. Evol. Biochem. Physiol., 53, No. 5, 431–434 (2017).

    Article  Google Scholar 

  37. Y. F. Pastukhov, V. V. Simonova, T. S. Shemyakova, et al., “U-133, a heat shock proteins inducer, precludes sleep disturbances in a model of the preclinical stage of Parkinson’s disease in aged rats,” Adv. Gerontol., 32, No. 6, 935 (2019).

  38. S. K. Calderwood, A. Murshid, and T. Prince, “The shock of aging: Molecular chaperones and the heat shock response in longevity and aging,” Gerontology, 55, No. 5, 550–558 (2009).

  39. N. Shemesh and A. Ben-Zvi, “HSF1 regulation in aging and its role in longevity,” in: Heat Shock Factor (2016), pp. 93–113.

  40. A. Y. Chesnokova, I. V. Ekimova, and Y. F. Pastukhov, “Parkinson’s disease and aging,” Adv. Gerontol., 9, No. 2, 164–173 (2019).

    Article  Google Scholar 

  41. W. W. Yu, S. N. Cao, C. X. Zang, et al., “Heat shock protein 70 suppresses neuroinflammation induced by α-synuclein in astrocytes,” Mol. Cell. Neurosci., 86, 58–64 (2018).

    Article  CAS  Google Scholar 

  42. I. V. Guzhova, Z. A. Darieva, A. R. Melo, and B. A. Margulis, “Major stress protein Hsp70 interacts with NF-kB regulatory complex in human T-lymphoma cells,” Cell Stress Chaperones, 2, No. 2, 132 (1997).

  43. A. Asea, S. K. Kraeft, E. A. Kurt-Jones, et al., “HSP70 stimulates cytokine production through a CD 14-dependent pathway, demonstrating its dual role as a chaperone and cytokine,” Nat. Med., 6, No. 4, 435–442 (2000).

    Article  CAS  Google Scholar 

  44. S. K. Calderwood, S. S. Mambula, P. J. Gray, and J. R. Theriault, “Extracellular heat shock proteins in cell signaling,” FEBS Lett., 581, No. 19, 3689–3694 (2007).

    Article  CAS  Google Scholar 

  45. M. Tunesi, I. Raimondi, T. Russo, et al., “Hydrogel-based delivery of Tat-fused protein Hsp70 protects dopaminergic cells in vitro and in a mouse model of Parkinson’s disease,” NPG Asia Mater., 11, No. 1, 1–15 (2019).

    Article  Google Scholar 

  46. D. V. Plaksina and I. V. Ekimova, “Age-related features of α-synuclein pathology in the brain on modeling the preclinical stage of Parkinson’s disease in rats,” Neurosci. Behav. Physiol., 50, No. 1, 109–114 (2020).

    Article  Google Scholar 

  47. K. L. Ma, L. K. Song, Y. H. Yuan, et al., “The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle,” Neuropharmacology, 82, 132–142 (2014).

    Article  CAS  Google Scholar 

  48. C. C. Raiss, T. S. Braun, I. B. M. Konings, et al., “Functionally different α-synuclein inclusions yield insight into Parkinson’s disease pathology,” Sci. Rep., 6, No. 1, 1–13 (2016).

    Article  Google Scholar 

  49. X. Q. Bao, X. L. Wang, and D. Zhang, “FLZ attenuates α-synuclein-induced neurotoxicity by activating heat shock protein 70,” Mol. Neurobiol., 54, No. 1, 349–361 (2017).

    Article  CAS  Google Scholar 

  50. J. P. Anderson, D. E. Walker, J. M. Goldstein, et al., “Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease,” J. Biol. Chem., 281, No. 40, 29739–29752 (2006).

    Article  CAS  Google Scholar 

  51. H. Sato, S. Arawaka, S. Hara, et al., “Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease,” J. Neurosci., 31, No. 46, 16884–16894 (2011).

    Article  CAS  Google Scholar 

  52. L. Xie, H. Kang, Q. Xu, et al., “Sleep drives metabolite clearance from the adult brain,” Science, 342, No. 6156, 373–377 (2013).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. V. Belan.

Additional information

Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 106, No. 10, pp. 1251–1265, October, 2020.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belan, D.V., Polonik, S.G. & Ekimova, I.V. Assessment of the Efficacy of Preventive Therapy with Chaperone Inducer U133 in a Model of the Preclinical Stage of Parkinson’s Disease in Elderly Rats. Neurosci Behav Physi 51, 673–680 (2021). https://doi.org/10.1007/s11055-021-01120-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-021-01120-3

Keywords

Navigation